Clinical Trials
15 trialsNCT06880523 2026-04-14
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT02537418 2026-03-27
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Canadian Cancer Trials Group
Phase 1 Active not recruiting
NCT03410615 2026-03-24
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03057106 2026-03-03
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03965468 2026-02-09
CHESS
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT02788773 2025-05-15
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02879162 2025-03-07
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
Canadian Cancer Trials Group
Phase 2 Completed
NCT02870920 2023-12-08
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03373760 2023-06-09
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT03007407 2022-12-05
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
NSABP Foundation Inc
Phase 2 Completed
NCT03101475 2022-05-31
ILOC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03319316 2022-01-10
SOLUTION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn